CareDx, Inc. (CDNA) stock
Close on Nov 11, 2026Market cap $4.26BP/E 34.0Yield –
CareDx, Inc. grew revenue 38.9% to $497.40M over the twelve months to Sep 30, 2026. Operating income rose 95.3% to $116.49M, moving the operating margin from 16.7% to 23.4%. At the latest close the market valued the company at $4.26B, 34.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $4.26B
- P/E ratio
- 34.0
- Price to sales
- 8.57
- Price to book
- 9.12
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $497.40M
- Net income
- $128.63M
- EPS, diluted
- $2.39
- Book value per share
- $8.50
- Diluted shares
- 55M
Trading
- Next earnings
- Feb 23, 2027 (estimated, after the close)
- Previous close
- $80.77
- Open
- $81.99
- Day's range
- $80.18 – $84.10
- Volume
- 771,029
- Average volume (20 days)
- 1,404,103
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.51
- 52-week range
- $15.15 – $90.87
- RSI (14 days)
- 59.7
- Volatility (1 year)
- 75.2%
- Relative volume
- 0.59×
- WACC
- 12.5%
On 1 of our idea list: Breakout quarter
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CDNA | S&P 500 | Difference | CDNA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +27.5% | -2.4% | +29.9 pts | ||
| 3 months | +71.9% | -1.2% | +73.0 pts | ||
| Year to date | +330.8% | +12.3% | +318.5 pts | ||
| 1 year | +383.7% | +12.4% | +371.3 pts | ||
| 3 years | +995.4% | +78.8% | +916.6 pts | +122.1% | +21.4% |
| 5 years | +72.1% | +75.2% | −3.0 pts | +11.5% | +11.9% |
| 10 years | +1929.3% | +311.1% | +1618.1 pts | +35.1% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CareDx filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
About CareDx
Services-Medical Laboratories
CareDx, Inc. is a precision medicine company specializing in solutions for transplant patients and organ health management. Operating as a single reportable segment, the organization provides non-invasive molecular testing, laboratory products, digital health applications, and specialized pharmacy services across the pre- and post-transplant continuum. Its commercial testing portfolio includes gene expression profiling and donor-derived cell-free DNA tests for kidney, heart, and lung transplant surveillance. Additionally, the company offers human leukocyte antigen typing products, diagnostic next-generation sequencing kits, and clinical workflow software. CareDx serves clinicians, transplant centers, dialysis centers, healthcare providers, and biopharmaceutical partners.
Company profile, executives and historyCareDx stock: common questions
What is CareDx's stock price?
CDNA closed at $81.17 on Nov 11, 2026, up 0.50% on the day. Over the past 52 weeks it traded between $15.15 and $90.87.
What is CareDx's market cap?
CareDx was worth $4.26B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CDNA's P/E ratio?
CDNA trades at 34.0 times earnings, based on diluted earnings per share of $2.39 over the twelve months to Sep 30, 2026.
How much revenue does CareDx make?
CareDx reported revenue of $497.40M for the twelve months to Sep 30, 2026, up 38.9% from a year earlier.
Does CareDx pay a dividend?
No. CareDx has not paid a cash dividend over the last twelve months.
When does CareDx report earnings next?
CareDx is expected to report Q4 FY2026 results on Feb 23, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CDNA stock performed over the past year?
Including dividends, CDNA returned +383.7% over the past year, against +12.4% for the S&P 500.
How many CDNA shares are sold short?
7M shares were sold short at the latest FINRA report, 14.36% of the float, or 5.3 days of average trading volume.
Who are CareDx's competitors?
Companies most similar to CareDx by business, industry and size include VCYT, BLLN, BNR, CAI, CSTL.
See a number that looks wrong?